2 growth stocks that could be big winners in the next decade and beyond!

Zaven Boyrazian explores two growth stocks from his portfolio that he believes are perfectly positioned to surge by 2033 and beyond.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Growth stocks are notoriously more volatile than other types of shares. And that’s something the recent stock market correction abruptly reminded investors of.

However, while the risk is certainly higher, these typically younger enterprises can enhance an investment portfolio to generate far superior returns in the long run.

The UK has its fair share of growth investments to pick from. But lately, I’ve had my eye on US tech stocks that continue to look like terrific opportunities even in the current economic climate.

With that in mind, let’s look at two firms from my portfolio that I’m currently tempted to add more of.

Driving drug development

It’s no secret that researching, developing, and eventually bringing new pharmaceutical drugs to the market is a challenging task. The process can take more than a decade from start to finish, costing billions along the way. That’s why pure-play pharmaceutical companies can be quite a risky investment.

However, one business that thrives even during failed clinical trials is Veeva Systems (NYSE:VEEV). The company provides a specialised CRM platform to aid pharmaceutical, biotech, medical device, and clinical research organisations in bringing new products to market faster without accidentally breaching compliance.

While there are alternative software solutions available, Veeva has managed to position itself as the industry standard, used by the biggest names in healthcare, including GSK, Moderna, Pfizer, AstraZeneca, Bristol Myers Squibb, and Novartis, among others.

While thousands of healthcare companies rely on Veeva, the bulk of the revenue stream stems from these industry leaders. As such, there is some sales concentration risk. If a key client decides to swap to an alternative solution, it could have a dire impact on the firm’s performance.

But with Veeva so heavily embedded into its customers’ operations, that’s far easier said than done. And since demand for new and effective medicine isn’t likely to disappear for decades, Veeva looks like a top-notch growth stock, in my eyes.

Powering the cloud

While Veeva’s platform is at the heart of healthcare, it wouldn’t function without cloud computing providers like Microsoft Azure. But, Azure itself is reliant on other firms to provide the critical hardware needed to create the necessary bandwidth for rapid computing.

Today, Cisco Systems is a key supplier to the cloud computing industry, providing critical hardware to data centres. But over the last decade, Arista Networks (NYSE:ANET) has been slowly pushing Cisco out of the market.

The group’s latest ethernet switching provides the largest bandwidth in the industry, far outperforming Cisco’s own technology.

Subsequently, Arista now controls more than 23% of the global ethernet switch market, versus only 7% in 2013. And this trend doesn’t look like it’s going to change anytime soon.

Similar to Veeva, Arista has a revenue concentration risk, with Microsoft and Meta Platform making up a ginormous chunk of its revenue stream. And the loss of one of these customers could have severe repercussions.

Nevertheless, management’s heavy investment in research & development has propelled the group to be significantly more technologically advanced than its competitors.

So much so that I believe Arista could become the new dominant industry leader within the next decade.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Zaven Boyrazian has positions in Arista Networks and Veeva Systems. The Motley Fool UK has recommended Arista Networks, AstraZeneca Plc, GSK, Meta Platforms, Microsoft, and Veeva Systems. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

10% dividend growth! 2 FTSE 100 stocks tipped to supercharge cash payouts

These FTSE 100 stocks have strong records of dividend growth. And they're expected to keep on delivering, as Royston Wild…

Read more »

Investing Articles

Down 17% in a month and yielding 7.39%! Is this FTSE 100 share a screaming buy for me?

When Harvey Jones bought Taylor Wimpey last year he thought this FTSE 100 share was a brilliant long-term buy-and-hold. Has…

Read more »

Investing Articles

Here’s how I’m using a £20k ISA to target £11k+ in income 30 years from now

Is it realistic to put £20k in an ISA now and earn over half that amount every year in passive…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

If I could only keep 5 UK stocks from my portfolio I’d save these

Harvey Jones is running through his portfolio of top UK stocks to see which ones he couldn't bear to do…

Read more »

Midnight is celebrated along the River Thames in London with a spectacular and colourful firework display.
Investing Articles

I’m aiming for a million buying unexciting shares!

By investing regularly in long-established, proven and even rather dull businesses, this writer plans to aim for a million. Here's…

Read more »

Investing Articles

3 things to consider before you start investing

Our writer draws on his stock market experience to consider a few vital lessons he would use to start investing…

Read more »

Investing Articles

Will this lesser-known £28bn growth stock be joining the FTSE 100 soon?

As the powers that be plan a reorganisation of Footsie listing rules, this massive under-the-radar growth stock could find its…

Read more »

Investing Articles

Fools wouldn’t touch these 5 FTSE 350 flops with a bargepole – how come I own 3 of them?

Harvey Jones took a chance on three struggling FTSE 350 stocks in the hope that they'd stage a dramatic recovery.…

Read more »